Kimberly-Clark Corporation
KMB Stock News
Latest KMB news
Kimberly-Clark offers remedies in bid for EU approval of Kenvue deal
Reuters · Wed, 23 Sep 2026 05:34:45 -0400
Kimberly-Clark has offered concessions to address EU antitrust concerns about its $40 billion bid for Tylenol maker Kenvue , a filing on the European Commission website showed on Wednesday.
5 Beaten-Down Dividend Kings Ready to Roar Back in 2027 (One Yields Over 5%)
24/7 Wall Street · Tue, 22 Sep 2026 09:12:16 -0400
While investors pile into pricey AI darlings, a handful of battle-tested Dividend Kings have quietly slipped to levels that scream value, and Wall Street analysts see serious upside ahead for 2027.
Clorox vs. Kimberly-Clark: Which Household Staples Dividend Is Safer
24/7 Wall Street · Mon, 21 Sep 2026 09:19:24 -0400
Both Clorox and Kimberly-Clark have raised their dividends for years and offer yields above 5%, but one of them is sitting on a payout that its own management quietly admits may not be sustainable.
The Dividend Kings Ranked By Quality Scores (September 2026)
Seeking Alpha · Fri, 18 Sep 2026 08:16:11 -0400
Dividend Kings have a 50+ year track record of increasing dividends, showcasing resilience through economic challenges. I rank the Dividend Kings using my 9F Quality Scores, blending qualitative and quantitative factors for a robust, investment-grade assessment. ADP stands out as the best total-return candidate. It is undervalued, high-quality, and offering a strong projected dividend growth rate and Adjusted Chowder Number.
Can Kimberly-Clark's Pricing Actions Offset Rising Input Cost Risks?
Zacks Investment Research · Thu, 17 Sep 2026 13:01:17 -0400
KMB is tackling $150 million of second-half input-cost pressure with targeted pricing, productivity gains and supplier actions.
Delta Air, Freeport-McMoRan, Kimberly-Clark And More On CNBC's ‘Final Trades'
Benzinga · Mon, 14 Sep 2026 07:54:10 -0400
On CNBC's “Halftime Report Final Trades,” Kevin Simpson, founder and CEO of Capital Wealth Planning, picked Freeport-McMoRan Inc. (NYSE:FCX) amid the recent pullback in copper.
Kimberly-Clark readies EU remedies in bid for Kenvue deal, sources say
Reuters · Mon, 14 Sep 2026 06:56:41 -0400
Kimberly-Clark is readying concessions to address EU antitrust concerns about its bid for Tylenol maker Kenvue that could help it win approval for the $40 billion deal after a preliminary review, people familiar with the matter said.
Market information is provided for research and visualization and is not investment advice.